Close

Arrowhead Research (ARWR) Tops Q3 EPS by 5c

Go back to Arrowhead Research (ARWR) Tops Q3 EPS by 5c

Arrowhead Reports Fiscal 2016 Third Quarter Results

August 9, 2016 4:01 PM EDT

Conference Call and Webcast Today at 4:30 p.m. EDT

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at... More

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

August 9, 2016 9:03 AM EDT

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million. The offering was priced at $5.90 per share.

Cantor Fitzgerald & Co. acted as sole placement agent for the offering.

Approximately 7.63 million shares of common stock are expected to be issued at the closing of the offering. The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions.

This press release shall not... More